350 related articles for article (PubMed ID: 26402079)
1. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study.
Eriksdotter M; Vedin I; Falahati F; Freund-Levi Y; Hjorth E; Faxen-Irving G; Wahlund LO; Schultzberg M; Basun H; Cederholm T; Palmblad J
J Alzheimers Dis; 2015; 48(3):805-12. PubMed ID: 26402079
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study.
Jernerén F; Cederholm T; Refsum H; Smith AD; Turner C; Palmblad J; Eriksdotter M; Hjorth E; Faxen-Irving G; Wahlund LO; Schultzberg M; Basun H; Freund-Levi Y
J Alzheimers Dis; 2019; 69(1):189-197. PubMed ID: 30958356
[TBL] [Abstract][Full Text] [Related]
3. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
Freund Levi Y; Vedin I; Cederholm T; Basun H; Faxén Irving G; Eriksdotter M; Hjorth E; Schultzberg M; Vessby B; Wahlund LO; Salem N; Palmblad J
J Intern Med; 2014 Apr; 275(4):428-36. PubMed ID: 24410954
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
[TBL] [Abstract][Full Text] [Related]
6. Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study.
Faxén-Irving G; Freund-Levi Y; Eriksdotter-Jönhagen M; Basun H; Hjorth E; Palmblad J; Vedin I; Cederholm T; Wahlund LO
J Alzheimers Dis; 2013; 36(1):1-6. PubMed ID: 23563245
[TBL] [Abstract][Full Text] [Related]
7. Lower omega-3 fatty acid intake and status are associated with poorer cognitive function in older age: A comparison of individuals with and without cognitive impairment and Alzheimer's disease.
Phillips MA; Childs CE; Calder PC; Rogers PJ
Nutr Neurosci; 2012 Nov; 15(6):271-7. PubMed ID: 22824373
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study.
Irving GF; Freund-Levi Y; Eriksdotter-Jönhagen M; Basun H; Brismar K; Hjorth E; Palmblad J; Vessby B; Vedin I; Wahlund LO; Cederholm T
J Am Geriatr Soc; 2009 Jan; 57(1):11-7. PubMed ID: 19054188
[TBL] [Abstract][Full Text] [Related]
9. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study.
Freund-Levi Y; Vedin I; Hjorth E; Basun H; Faxén Irving G; Schultzberg M; Eriksdotter M; Palmblad J; Vessby B; Wahlund LO; Cederholm T; Basu S
J Alzheimers Dis; 2014; 42(3):823-31. PubMed ID: 24934544
[TBL] [Abstract][Full Text] [Related]
10. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
[TBL] [Abstract][Full Text] [Related]
11. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study.
Vedin I; Cederholm T; Freund-Levi Y; Basun H; Garlind A; Irving GF; Eriksdotter-Jönhagen M; Wahlund LO; Dahlman I; Palmblad J
PLoS One; 2012; 7(4):e35425. PubMed ID: 22545106
[TBL] [Abstract][Full Text] [Related]
12. No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A Randomised Controlled Trial.
Phillips MA; Childs CE; Calder PC; Rogers PJ
Int J Mol Sci; 2015 Oct; 16(10):24600-13. PubMed ID: 26501267
[TBL] [Abstract][Full Text] [Related]
13. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
[TBL] [Abstract][Full Text] [Related]
14. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.
Geleijnse JM; Giltay EJ; Kromhout D
Alzheimers Dement; 2012 Jul; 8(4):278-87. PubMed ID: 21967845
[TBL] [Abstract][Full Text] [Related]
15. Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study.
Vedin I; Cederholm T; Freund Levi Y; Basun H; Garlind A; Faxén Irving G; Jönhagen ME; Vessby B; Wahlund LO; Palmblad J
Am J Clin Nutr; 2008 Jun; 87(6):1616-22. PubMed ID: 18541548
[TBL] [Abstract][Full Text] [Related]
16. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study.
Karimi M; Vedin I; Freund Levi Y; Basun H; Faxén Irving G; Eriksdotter M; Wahlund LO; Schultzberg M; Hjorth E; Cederholm T; Palmblad J
Am J Clin Nutr; 2017 Oct; 106(4):1157-1165. PubMed ID: 28855224
[No Abstract] [Full Text] [Related]
17. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a systematic review and meta-analysis.
Hooijmans CR; Pasker-de Jong PC; de Vries RB; Ritskes-Hoitinga M
J Alzheimers Dis; 2012; 28(1):191-209. PubMed ID: 22002791
[TBL] [Abstract][Full Text] [Related]
18. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease.
Rijpma A; Meulenbroek O; van Hees AM; Sijben JW; Vellas B; Shah RC; Bennett DA; Scheltens P; Olde Rikkert MG
Alzheimers Res Ther; 2015; 7(1):51. PubMed ID: 26213579
[TBL] [Abstract][Full Text] [Related]
19. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
[TBL] [Abstract][Full Text] [Related]
20. Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study.
Vedin I; Cederholm T; Freund-Levi Y; Basun H; Hjorth E; Irving GF; Eriksdotter-Jönhagen M; Schultzberg M; Wahlund LO; Palmblad J
J Lipid Res; 2010 May; 51(5):1179-85. PubMed ID: 19965584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
